Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer

Table 3

Incidence of drug-related toxicities grades 2 to 4.

Toxicity	Docetaxel + capecitabine		Paclitaxel + capecitabine
	𝑁=19		𝑁=18
	Grade I and II	Grade III and IV	Grade I and II	Grade III and IV
Hematological
Leukopenia	3 (15.8%)	9 (47.4%)	10 (55.6%)	0	𝑃=0.001
Neutropenia	0	12 (63.2%)	9 (50.0%)	3 (16.7%)	𝑝=0005
Febrile neutropenia	NA	1 (5.3%)	NA	1 (5,6%)	n.s.
Anemia	3 (15.8%)	0	14 (77.8%)	0	0.002
Non-hematological
Infection	NA	1 (5.3%)	NA	2 (11.1%)	n.s.
Mucositis	9 (47.4%)	0	5 (27.8%)	0	N.s.
Pain	5 (26.3%)	0	6 (33.3%)	1 (5.6%)	n.s.
Fatigue	7 (36.8%)	1 (5.3%)	12 (67.7%)	1 (5.6%)	n:s
Diarrhoea	7 (36.8%)	0	3 (16.7%)	0	n.s.
Neuropathy, sensory	3 (15.8%)	0	7 (38.9%)	0	n.s.
PPE*	8 (42.1%)	1 (5.3%)	9 (50%)	4 (22.2%)	n.s.
Nail changes	7 (36.8%)	1 (5.3%)	11 (55.6%)	1 (5.6)	n.s.

*Palmar-Plantar Erythrodysesthesia.